Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease.
Fernando Caravaca-FontánMontserrat M Díaz-EncarnaciónLaura LucientesTeresa CaveroVirginia CabelloGema AricetaLuis F QuintanaHelena MarcoXoana BarrosNatalia RamosNuria Rodríguez-MendiolaSonia CruzGema Fernández-JuárezAdela RodríguezAna Pérez de JoséCristina RabascoRaquel RodadoLoreto FernándezVanessa Pérez GómezAna I ÁvilaLuis BravoJavier LumbrerasNatalia AllendeMaria Dolores Sanchez de la NietaEva RodríguezTeresa OleaMarta MelgosaAna HuertaRosa MiquelCarmen MonGloria FragaAlberto de LorenzoJuliana DraibeMarta Cano-MegíasFayna GonzálezAmir ShabakaMaria Esperanza López-RubioMaría Ángeles FenollosaLuis Martín-PenagosIara Da SilvaJuana Alonso TitosSantiago Rodríguez de CórdobaElena Goicoechea de JorgeManuel Praganull nullPublished in: Clinical journal of the American Society of Nephrology : CJASN (2020)
The beneficial response to corticosteroids plus MMF treatment in C3 glomerulopathy appears independent of the pathogenic drivers analyzed in this study.
Keyphrases